Brown Capital Management LLC Sells 22,407 Shares of Masimo Co. (NASDAQ:MASI)

Brown Capital Management LLC reduced its stake in Masimo Co. (NASDAQ:MASI - Free Report) by 83.6% during the 3rd quarter, according to the company in its most recent filing with the SEC. The fund owned 4,404 shares of the medical equipment provider's stock after selling 22,407 shares during the quarter. Brown Capital Management LLC's holdings in Masimo were worth $587,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. NBC Securities Inc. raised its stake in Masimo by 47.1% in the third quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider's stock valued at $30,000 after buying an additional 73 shares in the last quarter. GAMMA Investing LLC raised its holdings in Masimo by 75.0% during the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider's stock worth $33,000 after purchasing an additional 111 shares in the last quarter. Northwestern Mutual Wealth Management Co. boosted its stake in shares of Masimo by 133.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider's stock valued at $44,000 after buying an additional 200 shares in the last quarter. Lazard Asset Management LLC grew its stake in shares of Masimo by 5,730.0% during the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider's stock worth $85,000 after purchasing an additional 573 shares during the period. Finally, HHM Wealth Advisors LLC grew its holdings in shares of Masimo by 25.0% in the 2nd quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider's stock worth $79,000 after acquiring an additional 125 shares during the period. 85.96% of the stock is owned by institutional investors and hedge funds.

Masimo Stock Performance

Masimo stock traded up $4.17 on Thursday, hitting $169.12. The company's stock had a trading volume of 543,266 shares, compared to its average volume of 676,303. The firm has a market cap of $9.05 billion, a P/E ratio of 113.76 and a beta of 0.97. The company has a quick ratio of 1.11, a current ratio of 2.01 and a debt-to-equity ratio of 0.50. Masimo Co. has a one year low of $91.60 and a one year high of $173.90. The company has a fifty day moving average price of $141.16 and a 200-day moving average price of $127.47.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings data on Tuesday, November 5th. The medical equipment provider reported $0.98 EPS for the quarter, topping analysts' consensus estimates of $0.84 by $0.14. Masimo had a net margin of 3.85% and a return on equity of 14.98%. The firm had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. During the same quarter in the prior year, the firm earned $0.63 EPS. The company's revenue was up 5.4% on a year-over-year basis. On average, equities analysts anticipate that Masimo Co. will post 4.04 earnings per share for the current year.

Analyst Ratings Changes

A number of research firms have recently weighed in on MASI. BTIG Research boosted their price target on Masimo from $166.00 to $170.00 and gave the stock a "buy" rating in a report on Monday, October 14th. Piper Sandler raised their price target on shares of Masimo from $165.00 to $180.00 and gave the company an "overweight" rating in a report on Wednesday, November 6th. Needham & Company LLC reiterated a "hold" rating on shares of Masimo in a research note on Wednesday, November 6th. Raymond James raised Masimo from a "market perform" rating to an "outperform" rating and set a $170.00 price target for the company in a report on Wednesday, November 6th. Finally, Wells Fargo & Company lifted their price target on Masimo from $160.00 to $171.00 and gave the stock an "overweight" rating in a research note on Wednesday, November 6th. Three equities research analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $163.67.

Masimo Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.